leisure time -WSS

leisure time

author：focus 2025-09-27 22:59:28 - browse：32

The biotech company Acelyrin, which raised more than $500 million in an IPO this year, ran into its first major setback Monday as its investigational anti-inflammatory drug missed the primary goal in a pivotal clinical trial.

Acelyrin’s medicine, a subcutaneous treatment called izokibep, is meant to clear up lesions for patients with the common skin disease hidradenitis suppurativa, or HS, an inflammatory disorder that leads to abscesses and scars. But after 16 weeks of treatment, patients who received izokibep did not show significant improvements compared to those taking a placebo, failing the study’s primary endpoint.

Acelyrin’s share price fell more than 60% in after-hours trading Monday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Winners, losers from Medicare’s list of drugs subject to price talks

WSS

Australia’s approach to dialysis celebrates life

Study finds new variant for Parkinson’s in African populations

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

STAT Madness 2024: Meet the contenders

Using force crossed my mind when examining a defiant young patient

How to make Best Hospitals ratings actually useful for patients

hotspot

leisure time

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

Virtual repurposing can help discover new uses for existing drugs

ChatGPT in medicine: STAT answers readers' burning questions

Radiation, mainstay of cancer treatment, begins a fade

Medicare proposal to cover medical devices draws a mixed reaction

Using force crossed my mind when examining a defiant young patient

The high cost of giving birth even with insurance

AstraZeneca bets AAV gene therapy will still deliver the goods

Hollywood unions extend contract negotiations for actors

How to make Best Hospitals ratings actually useful for patients

entertainment

CDC advisory panel says seniors 'may' get RSV vaccine

How Long Island became the ‘eugenics capital of the world’

Medicare isn't yet testing food as medicine

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

Appeals court upholds limits to abortion pill

CDC advisory group OKs chikungunya vaccine

leisure time

focus

focus

entertainment